The FPR2-induced rise in cytosolic calcium in human neutrophils relies on an emptying of intracellular calcium stores and is inhibited by a gelsolin-derived PIP2-binding peptide
© Forsman and Dahlgren; licensee BioMed Central Ltd. 2010
Received: 13 February 2010
Accepted: 6 July 2010
Published: 6 July 2010
The molecular basis for neutrophil recognition of chemotactic peptides is their binding to specific G-protein-coupled cell surface receptors (GPCRs). Human neutrophils express two pattern recognition GPCRs, FPR1 and FPR2, which belong to the family of formyl peptide receptors. The high degree of homology between these two receptors suggests that they share many functional and signal transduction properties, although they exhibit some differences with respect to signaling. The aims of this study were to determine whether FPR2 triggers a unique signal that allows direct influx of extracellular calcium without the emptying of intracellular calcium stores, and whether the gelsolin-derived PIP2-binding peptide, PBP10, selectively inhibits FPR2-mediated transient rise in intracellular Ca2+.
The transient rise in intracellular Ca2+ induced by agonists for FPR1 or FPR2 in human neutrophils occurred also in the presence of a chelator of Ca2+ (EGTA). PBP10 inhibited not only FPR2-induced oxidase activity, but also the transient rise in intracellular Ca2+.
Ca2+ signaling mediated via FPR2 follows the same route as FPR1, which involves initial emptying of the intracellular stores. PBP10 inhibits selectively the signals generated by FPR2, both with respect to NADPH-oxidase activity and the transient rise in intracellular Ca2+ induced by agonist exposure.
Neutrophil granulocytes are crucial for the outcome of the "battle" between the innate immune system and invading micro-organisms, and are key cells in the damaged tissues at sites of infection and inflammation. Neutrophil responses to endogenous and exogenous chemoattractants include locomotory responses, up-regulation of adhesion molecules, secretion of granule constituents, and production of reactive oxygen species (ROS), which are generated by the electron-transporting NADPH-oxidase system [1–3]. The molecular basis for cellular recognition of chemoattractants is their binding to specific cell surface receptors [4–8]. Despite the structural variability of the numerous extracellular ligands, many of them bind to (and activate) specific receptors belonging to a large family of pertussis toxin-sensitive, G-protein-coupled receptors (GPCRs). These receptors share a high degree of amino acid sequence similarity, and although they are activated by different agonists, they transduce downstream signals that have many common features. Nevertheless, it is clear that there are also important differences between the receptor-ligand pairs in terms of functional repertoires [9, 10]. The pattern recognition formyl peptide receptor (FPR) family belongs to the GPCR group of chemoattractant receptors, and human neutrophil granulocytes express two members of this family, i.e., FPR1 and FPR2 [4, 11]. FPR2 was originally defined as an orphan receptor, and the gene was cloned from an HL-60 cell cDNA library by low-stringency hybridization with the FPR1 sequence [12–14]. Recently, several FPR2-specific ligands have been identified [4, 11], including mitochondrial and microbial peptides [15, 16], various antimicrobial peptides , the acute phase protein serum amyloid A (SAA) [18, 19], the neurotoxic prion peptide fragment 106-126 , and synthetic peptides, such as WKYMVM  and MMK-1 . To date, no defined structure has been identified as the determinant for FPR2 binding and activation, although the close relationship between structural variation and function is illustrated by the fact that exchange of the C-terminal L-methionine residue in WKYMVM for the D-isomeric form expands the binding specificity to encompass both FPR2 and FPR1 .
The many studies that have been performed on FPR1-induced cell functions and signaling reveal that FPR1 signaling has all the characteristics of a pertussis toxin-sensitive GPCR. The activated receptor initiates a chain of signaling events, starting with dissociation of the receptor-associated G-protein, and subsequently, activation of a number of downstream signaling pathways. In one of these pathways, activation of phosphoinositide-specific phospholipase C (PLC) generates a second messenger following cleavage of PIP2, and this is the starting signal for a transient increase in cytosolic free calcium. Binding of the cleavage product, IP3, to its receptor located on storage organelles results in the release of Ca2+ from these intracellular organelles and elevation consequent increase in the concentration of free calcium ions in the cytoplasm [Ca2+]i . Emptying of the storage organelles leads to the entry of extracellular Ca2+ through store-operated calcium channels in the plasma membrane, thereby prolonging the increase in [Ca2+]i [25, 26].
Although our knowledge of the signal transduction pathways utilized by FPR2 is currently somewhat limited, the significant homology observed between FPR1 and FPR2 (69% at the amino acid level) suggests that these two receptors share signal transduction features. Accordingly, we have previously shown that the functional responses induced by the FPR2-specific agonist WKYMVM is largely similar to (even indistinguishable from) those induced by the prototype FPR1 agonist fMLF . However, fundamental differences between the signaling profiles of these two receptors have been described; the PIP2-binding peptide PBP10  selectively inhibits a signaling pathway triggered by FPR2, without affecting signaling via FPR1 . FPR2 has also been shown to trigger a unique type of Ca2+ influx across the plasma membrane . It has been suggested that a channel in the plasma membrane opens without involvement of the intracellular storage organelles. Thus, the influx of Ca2+ across the plasma membrane is not preceded by an increase in [Ca2+]i that originates from the release of Ca2+ from the intracellular stores . These results point to two important differences in the signaling mediated by the two FPRs in human neutrophils. Whereas FPR2 triggers a unique calcium signal, which is independent of the intracellular Ca2+ store-influenced Ca2+ channels, and allows for the direct influx of extracellular Ca2+, a PIP2-binding peptide inhibits FPR2-induced (but not FPR1-induced) radical production by neutrophils. It is noteworthy that the influx of calcium induced by FPR2 is apparently insensitive to PBP10 treatment . The mechanism underlying these differences is puzzling and it is thus of importance to verify or falsify the observations.
In the present study, we characterize the neutrophil responses to the FPR2-specific agonist WKYMVM. We confirm the difference between FPR1-dependent and FPR2-dependent activation of the neutrophil NADPH-oxidase. However, in apparent discrepancy with previously published results [28, 29], we show that the FPR2 agonist induces an increase in [Ca2+]i that involves Ca2+ release from intracellular stores, and this signaling pathway is inhibited by the FPR2-specific inhibitor PBP10.
The fMLF and WKYMVM peptides activate the NADPH-oxidase in neutrophils
The fMLF and WKYMVM peptides mobilize intracellular Ca2+ in neutrophils
The PIP2-binding peptide PBP10 inhibits the neutrophil calcium response to the FPR2 agonist WKYMVM
The sensitivity of the calcium measurement system is very low when high concentrations of agonist (10-7 M) are used, and we set out to determine if the insensitivity to PBP10 of the WKYMVM induced response, is due to the concentration used. We found that when the concentration of agonist was reduced (from 10-7 M, the final concentration used in Fig 3A) to 10 nM or 5 nM, the response triggered by WKYMVM was completely inhibited by PBP10 (Fig 3B). Lower concentrations of WKYMVM did not evoke any Ca2+ response. In contrast to the situation observed for WKYMVM, there was no inhibition by PBP10 when the concentration of fMLF was reduced to 1 nM, which was the lowest concentration to induce a response (Fig 3B). These data clearly show that the PBP10 peptide selectively inhibits the calcium response mediated by FPR2.
The transient increases in intracellular Ca2+ induced by FPR1 and FPR2 rely on mobilization of Ca2+ from intracellular storage organelles
Human neutrophils express the formyl peptide receptor family members FPR1 and FPR2, which share a high degree of amino acid sequence identity. Despite the similarities between the two receptors, the signaling events that follow receptor occupancy and activation differ. These differences may be related either to a specific agonist or distinct difference(s) between the receptors [4, 31]. We have previously shown that a receptor agonist that binds to both FPR1 and FPR2 can trigger receptor-specific signals, and depending on the particular triggering agonist, both receptors can either inhibit the functional repertoire of the neutrophils or activate the same repertoire [32–34]. One of the early signals generated by activated neutrophil GPCRs (including FPR1 and FPR2) is the rapid rise of [Ca2+]i, which affects different cellular functions. For a resting neutrophil, the free cytosolic calcium concentration is maintained at a very low level (approximately 100 nM) relative to the level in the extracellular fluid (approximately 1 mM). To maintain this concentration gradient, cells are equipped with ion pumps that transport Ca2+ out of the cells as well as to the intracellular calcium storing organelles, which contain high levels of the calcium-binding protein calreticulin. It is generally accepted that the main pathway for the control of rapid changes of [Ca2+]i in neutrophils is that represented by the capacitive model, which starts with the production of inositol-1,4,5-trisphosphate (IP3). The main pathway for IP3 production involves PLC-mediated hydrolysis of membrane PIP2; the generated IP3 releases calcium from intracellular stores by binding to specific receptors on the intracellular storage organelles. The depletion of the intracellular Ca2+ stores regulates the opening of store-operated Ca2+ channels (SOC) in the plasma membrane, thereby providing a rich source of capacitive entry of calcium ions, originating from the extracellular space [26, 35, 36]. With respect to the different signaling properties of the FPRs, a recent report has demonstrated that the regulatory mechanism that leads to an increase in [Ca2+]i is unique to FPR2. Binding of an agonist to either of the two FPRs results in a signaling cascade, which in turn leads to an increase in intracellular calcium through the influx of ions across the plasma membrane. Whereas FPR1 influences the plasma membrane channels through the emptying of intracellular stores, as described above, FPR2 appears to generate a signal that acts directly on the ion channels in the plasma membrane so as to facilitate the influx of Ca2+ independently of the filling status of the storage organelles .
Although we could not verify this difference in signaling profile, we show that the signals from FPR1 and FPR2 initiate an increase in cytosolic free calcium derived from the emptying of intracellular stores. The increase in [Ca2+]i was achieved when the calcium in the extracellular milieu was depleted through the addition of EGTA; these data are in accordance with recent results from experiments in which a much higher concentration (10-7 M) of agonist was used . With respect to the different signaling properties of the two receptors, we recently showed that FPR1 and FPR2 have different sensitivities to PBP10 . PBP10 inhibits FPR2-triggered activation of the neutrophil NADPH-oxidase. However, when this system was directly transferred to a calcium measurement system, we found that the cytosolic increase in free Ca2+ was largely insensitive to PBP10.
In the present study, we confirm the difference between FPR1-dependent and FPR2-dependent activation of the neutrophil NADPH-oxidase. Moreover, we show that PBP10 inhibits not only the oxidase activity, but also the FPR2-induced increase in [Ca2+]i. The transient rise in [Ca2+]i peaks at agonist concentrations that are much lower than those used in the oxidase assay, and the inhibitory effects of PBP10 are, thus, disclosed only when the concentration of the FPR2 agonist is reduced. No inhibitory effect of PBP10 is seen when fMLF is used as the agonist, irrespective of the concentration of the chemoattractant used to activate the neutrophils.
The molecular mechanism underlying the effects of PBP10 on FPR2-mediated induction of cell functions is complex. PBP10 displays clearly higher specificity for FPR2 than for FPR1, although this pattern of sensitivity is not unique to this receptor [15, 18]. The biochemical and biophysical characterizations of the ten strategically organized basic and hydrophobic amino acids in PBP10, which are also present in the gelsolin molecule, suggest that it may interact with a broad range of negatively charged phosphomonoesters and hydrophobic acyl chains on anionic phospholipids. This implies that in addition to its blocking/competing activities, which involve proteins that are regulated by cellular phosphoinositides, PBP10 may affect the functions of bioactive and signaling lipids. Although the precise signal transduction step that is disrupted by PBP10 remains to be elucidated, the receptor-specific and signal-selective effects of this peptide on neutrophil functions suggest that it has potential applications as a tool to manipulate and define how G-protein-coupled receptors produce and integrate the signals generated from activated receptors, as well as to probe new signaling functions of polyphosphoinositides.
The neutrophil FPR family members FPR1 and FPR2 share 69% amino acid identity and mediate almost indistinguishable cellular responses. Therefore, these two FPRs use the same basic signaling pathways. Accordingly, we show that Ca2+ signaling mediated via FPR2 follows the same route as FPR1-mediated signaling, which involves initial emptying of the intracellular stores. However, we found that the FPR2-mediated oxidase activity and Ca2+ signaling pathway are inhibited by the FPR2-specific inhibitor PBP10, whereas there is no inhibitory effect of PBP10 when the high affinity FPR1 agonist fMLF is used, irrespective of the concentration of the chemoattractant used to activate the neutrophils. These data clearly demonstrate that there is a fundamental difference between the two very closely related receptor members, in that one is PBP10-sensitive (FPR2) and the other (FPR1) is PBP10-insensitive.
Peptides and reagents
The hexapeptide WKYMVM was synthesized and purified by Alta Bioscience (University of Birmingham, UK). The formylated peptide N-formylmethionyl-leucyl-phenylalanine (fMLF) was purchased from Sigma Chemical Co. (St. Louis, MO). The peptides were dissolved in dimethyl sulfoxide to a concentration of 10-2 M, and stored at -70°C until use. Further dilutions were made in Krebs-Ringer phosphate buffer that was supplemented with glucose (10 mM), Ca2+ (1 mM), and Mg2+ (1.5 mM) (KRG).
Determination of changes in cytosolic calcium
Cells at the density of 1-3 × 106 per ml were washed with Ca2+-free KRG and centrifuged at 220 × g. The cell pellets were resuspended at a density of 2 × 107 cells/ml in KRG that contained 0.1% BSA, and loaded with 2 μM Fura 2-AM (Molecular Probes, Eugene, OR) for 30 minutes at room temperature. The cells were then diluted to twice the original volume with RPMI 1640 culture medium without phenol red (PAA Laboratories GmbH, Pasching, Austria) and centrifuged. Finally, the cells were washed once with KRG, and resuspended in the same buffer at a density of 2 × 107 cells/ml. Calcium measurements were carried out in a Perkin Elmer fluorescence spectrophotometer (LC50), with excitation wavelengths of 340 nm and 380 nm, an emission wavelength of 509 nm, and slit widths of 5 nm and 10 nm, respectively. The transient rise in intracellular calcium is presented as the ratio of fluorescence intensities (340 nm: 380 nm) detected. The measuring cuvette contained catalase (2000 U), to counteract inactivation of the chemoattractants by the MPO-H2O2-system .
The concentration of EGTA required to achieve a calcium-free environment was determined by titration of the ionomycin-triggered production of oxidants by neutrophils resuspended in KRG that contained 1 mM Ca2+. A small volume (10 μl) of EGTA-containing buffer was added to the measuring vial, and 20 seconds later the cells were activated by the addition of ionomycin (5 × 10-7 M final concentration). The lowest concentration of EGTA that inhibited more than 90% of the ionomycin-induced response was used in subsequent studies to ensure that no Ca2+ entered the cells across the plasma membrane.
NADPH-oxidase activity measurements
Neutrophils (5 × 106 cells/ml) were incubated at 37°C for 5 minutes in an NADPH-oxidase measuring apparatus (Berthold Co., Wildbad, Germany). The activity of the cells was then using a luminol/isoluminol-enhanced chemiluminescence (CL) system [39, 40]. The extracellular CL activity was measured in a six-channel Biolumat LB 9505, using disposable polypropylene tubes with a 0.90-ml reaction mixture. The mixture contained neutrophils (5 × l05 cells/ml), horse radish peroxidase (HRP; 4U) and isoluminol (a cell-impermeable CL substrate; 2 × 10-5 M). The tubes were equilibrated at 37°C for 5 minutes in the absence or presence of inhibitor, after which the stimulus (0.1 ml) was added. The light emission was recorded continuously.
To determine intracellular NADPH-oxidase activity levels, we used mixtures that contained 5 × 105 neutrophils/ml, superoxide dismutase (SOD; a cell-impermeable superoxide scavenger; 200 U), catalase (2000 U), and luminol (a cell-permeable CL substrate; 2 × 10-5 M). The tubes were equilibrated at 37°C for 5 minutes in the luminometer, after which the stimulus (0.1 ml) was added, and light emission was recorded continuously.
H.F. is supported by a grant from the Swedish Society for Medical Research. The work was supported by grants from the Swedish Medical Research Council, the Inga Lisa and Arne Lundberg foundation, the King Gustaf V 80-Year Foundation, and the Swedish state under the ALF agreement. None of the funding bodies had any role in the study design, in the collection or analysis of data, in writing the manuscript or in the decision to submit the manuscript for publication.
- Bokoch GM: Chemoattractant signaling and leukocyte activation. Blood. 1995, 86: 1649-60.PubMed
- Bokoch GM, Knaus UG: NADPH oxidases: not just for leukocytes anymore!. Trends Biochem Sci. 2003, 28: 502-8. 10.1016/S0968-0004(03)00194-4.View ArticlePubMed
- Edwards SW: Biochemistry and physiology of the neutrophil. 1994, New York: Cambridge University Press, NY, USAView Article
- Fu H, Karlsson J, Bylund J, Movitz C, Karlsson A, Dahlgren C: Ligand recognition and activation of formyl peptide receptors in neutrophils. J Leukoc Biol. 2006, 79: 247-56. 10.1189/jlb.0905498.View ArticlePubMed
- Miller AF, Falke JJ: Chemotaxis receptors and signaling. Adv Protein Chem. 2004, 68: 393-444. full_text.View ArticlePubMed
- Murphy PM: The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol. 1994, 12: 593-633. 10.1146/annurev.iy.12.040194.003113.View ArticlePubMed
- Rabiet MJ, Huet E, Boulay F: The N-formyl peptide receptors and the anaphylatoxin C5a receptors: an overview. Biochimie. 2007, 89: 1089-106. 10.1016/j.biochi.2007.02.015.View ArticlePubMed
- Ye RD, Boulay F: Structure and function of leukocyte chemoattractant receptors. Adv Pharmacol. 1997, 39: 221-89. full_text.View ArticlePubMed
- Heit B, Tavener S, Raharjo E, Kubes P: An intracellular signaling hierarchy determines direction of migration in opposing chemotactic gradients. J Cell Biol. 2002, 159: 91-102. 10.1083/jcb.200202114.PubMed CentralView ArticlePubMed
- Baggiolini M: Introduction to chemokines and chemokine antagonists. Ernst Schering Res Found Workshop. 2004, 1-9.
- Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M, Serhan CN, Murphy AP: International Union of Basic and Clinical Pharmacology. LXXIII. Nomenclature for the Formyl Peptide Receptor (FPR) Family. Pharmacol Rev. 2009
- Boulay F, Tardif M, Brouchon L, Vignais P: Synthesis and use of a novel N-formyl peptide derivative to isolate a human N-formyl peptide receptor cDNA. Biochem Biophys Res Commun. 1990, 168: 1103-9. 10.1016/0006-291X(90)91143-G.View ArticlePubMed
- Boulay F, Tardif M, Brouchon L, Vignais P: The human N-formylpeptide receptor. Characterization of two cDNA isolates and evidence for a new subfamily of G-protein-coupled receptors. Biochemistry. 1990, 29: 11123-33. 10.1021/bi00502a016.View ArticlePubMed
- Ye RD, Cavanagh SL, Quehenberger O, Prossnitz ER, Cochrane CG: Isolation of a cDNA that encodes a novel granulocyte N-formyl peptide receptor. Biochem Biophys Res Commun. 1992, 184: 582-9. 10.1016/0006-291X(92)90629-Y.View ArticlePubMed
- Bellner L, Karlsson J, Fu H, Boulay F, Dahlgren C, Eriksson K, Karlsson A: A monocyte-specific peptide from herpes simplex virus type 2 glycoprotein G activates the NADPH-oxidase but not chemotaxis through a G-protein-coupled receptor distinct from the members of the formyl peptide receptor family. J Immunol. 2007, 179: 6080-7.View ArticlePubMed
- Rabiet MJ, Huet E, Boulay F: Human mitochondria-derived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenes-derived peptides preferentially activate FPR. Eur J Immunol. 2005, 35: 2486-95. 10.1002/eji.200526338.View ArticlePubMed
- Bylund J, Christophe T, Boulay F, Nystrom T, Karlsson A, Dahlgren C: Proinflammatory activity of a cecropin-like antibacterial peptide from Helicobacter pylori. Antimicrob Agents Chemother. 2001, 45: 1700-4. 10.1128/AAC.45.6.1700-1704.2001.PubMed CentralView ArticlePubMed
- Bjorkman L, Karlsson J, Karlsson A, Rabiet MJ, Boulay F, Fu H, Bylund J, Dahlgren C: Serum amyloid A mediates human neutrophil production of reactive oxygen species through a receptor independent of formyl peptide receptor like-1. J Leukoc Biol. 2008, 83: 245-53. 10.1189/jlb.0607-408.View ArticlePubMed
- Su SB, Gong W, Gao JL, Shen W, Murphy PM, Oppenheim JJ, Wang JM: A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J Exp Med. 1999, 189: 395-402. 10.1084/jem.189.2.395.PubMed CentralView ArticlePubMed
- Le Y, Gong W, Tiffany HL, Tumanov A, Nedospasov S, Shen W, Dunlop NM, Gao JL, Murphy PM, Oppenheim JJ: Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J Neurosci. 2001, 21: RC123-PubMed
- Christophe T, Karlsson A, Dugave C, Rabiet MJ, Boulay F, Dahlgren C: The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. J Biol Chem. 2001, 276: 21585-93. 10.1074/jbc.M007769200.View ArticlePubMed
- Hu JY, Le Y, Gong W, Dunlop NM, Gao JL, Murphy PM, Wang JM: Synthetic peptide MMK-1 is a highly specific chemotactic agonist for leukocyte FPRL1. J Leukoc Biol. 2001, 70: 155-61.PubMed
- Dahlgren C, Christophe T, Boulay F, Madianos PN, Rabiet MJ, Karlsson A: The synthetic chemoattractant Trp-Lys-Tyr-Met-Val-DMet activates neutrophils preferentially through the lipoxin A(4) receptor. Blood. 2000, 95: 1810-8.PubMed
- Berridge MJ: Inositol trisphosphate and calcium signalling. Nature. 1993, 361: 315-25. 10.1038/361315a0.View ArticlePubMed
- Favre CJ, Nusse O, Lew DP, Krause KH: Store-operated Ca2+ influx: what is the message from the stores to the membrane?. J Lab Clin Med. 1996, 128: 19-26. 10.1016/S0022-2143(96)90110-9.View ArticlePubMed
- Putney JW: Recent breakthroughs in the molecular mechanism of capacitative calcium entry (with thoughts on how we got here). Cell Calcium. 2007, 42: 103-10. 10.1016/j.ceca.2007.01.011.PubMed CentralView ArticlePubMed
- Cunningham CC, Vegners R, Bucki R, Funaki M, Korde N, Hartwig JH, Stossel TP, Janmey PA: Cell permeant polyphosphoinositide-binding peptides that block cell motility and actin assembly. J Biol Chem. 2001, 276: 43390-9. 10.1074/jbc.M105289200.View ArticlePubMed
- Fu H, Bjorkman L, Janmey P, Karlsson A, Karlsson J, Movitz C, Dahlgren C: The two neutrophil members of the formylpeptide receptor family activate the NADPH-oxidase through signals that differ in sensitivity to a gelsolin derived phosphoinositide-binding peptide. BMC Cell Biol. 2004, 5: 50-10.1186/1471-2121-5-50.PubMed CentralView ArticlePubMed
- Partida-Sanchez S, Iribarren P, Moreno-Garcia ME, Gao JL, Murphy PM, Oppenheimer N, Wang JM, Lund FE: Chemotaxis and calcium responses of phagocytes to formyl peptide receptor ligands is differentially regulated by cyclic ADP ribose. J Immunol. 2004, 172: 1896-906.View ArticlePubMed
- Forsman H, Salomonsson E, Onnheim K, Karlsson J, Bjorstad A, Leffler H, Bylund J, Karlsson A, Dahlgren C: The beta-galactoside binding immunomodulatory lectin galectin-3 reverses the desensitized state induced in neutrophils by the chemotactic peptide f-Met-Leu-Phe: role of reactive oxygen species generated by the NADPH-oxidase and inactivation of the agonist. Glycobiology. 2008, 18: 905-12. 10.1093/glycob/cwn081.View ArticlePubMed
- Lundqvist H, Dahlgren C: Isoluminol-enhanced chemiluminescence: a sensitive method to study the release of superoxide anion from human neutrophils. Free Radic Biol Med. 1996, 20: 785-92. 10.1016/0891-5849(95)02189-2.View ArticlePubMed
- Dahlgren C, Karlsson A: Respiratory burst in human neutrophils. J Immunol Methods. 1999, 232: 3-14. 10.1016/S0022-1759(99)00146-5.View ArticlePubMed
- Andersson T, Dahlgren C, Pozzan T, Stendahl O, Lew PD: Characterization of fMet-Leu-Phe receptor-mediated Ca2+ influx across the plasma membrane of human neutrophils. Mol Pharmacol. 1986, 30: 437-43.PubMed
- Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M, Serhan CN, Murphy PM: Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev. 2009,
- Fiore S, Maddox JF, Perez HD, Serhan CN: Identification of a human cDNA encoding a functional high affinity lipoxin A4 receptor. J Exp Med. 1994, 180: 253-60. 10.1084/jem.180.1.253.View ArticlePubMed
- Gavins FN, Sawmynaden P, Chatterjee BE, Perretti M: A twist in anti-inflammation: annexin 1 acts via the lipoxin A4 receptor. Prostaglandins Leukot Essent Fatty Acids. 2005, 73: 211-9. 10.1016/j.plefa.2005.05.008.View ArticlePubMed
- Karlsson J, Fu H, Boulay F, Dahlgren C, Hellstrand K, Movitz C: Neutrophil NADPH-oxidase activation by an annexin AI peptide is transduced by the formyl peptide receptor (FPR), whereas an inhibitory signal is generated independently of the FPR family receptors. J Leukoc Biol. 2005
- Putney JW: SOC: now also store-operated cyclase. Nat Cell Biol. 2009, 11: 381-2. 10.1038/ncb0409-381.View ArticlePubMed
- Putney JW, Bird GS: Cytoplasmic calcium oscillations and store-operated calcium influx. J Physiol. 2008, 586: 3055-9. 10.1113/jphysiol.2008.153221.PubMed CentralView ArticlePubMed
- Karlsson J, Stenfeldt AL, Rabiet MJ, Bylund J, Forsman HF, Dahlgren C: The FPR2-specific ligand MMK-1 activates the neutrophil NADPH-oxidase, but triggers no unique pathway for opening of plasma membrane calcium channels. Cell Calcium. 2009, 45: 431-8. 10.1016/j.ceca.2009.02.002.View ArticlePubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.